1460-38-4

Usage

Synthesis Reference(s)

Tetrahedron Letters, 31, p. 1157, 1990 DOI: 10.1016/S0040-4039(00)88751-1

InChI:InChI=1/C7H10O3/c8-6-3-1-2-5(6)4-7(9)10/h5H,1-4H2,(H,9,10)

Upstream product

• 41301-66-0 ethyl 1-(2-ethoxy-2-oxoethyl)-2-oxocyclopentanecarboxylate 
• 91783-90-3 Cyclopentanon-⁽²⁾-oxalsaeure-⁽¹⁾ 
• 105-39-5 chloroacetic acid ethyl ester 
• 100796-98-3 {2-[(2,4-Dinitro-phenyl)-hydrazono]-cyclopentyl}-acetic acid 
• 844874-18-6 exo-2,3-epoxynorbornane 
• 7647-01-0 hydrogenchloride 
• 20826-94-2 ethyl (2-oxocyclopentyl)acetate 
• 40702-70-3 ethyl 2-oxo-cyclopentanecarboxylate potassium salt 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 141-28-6 diethyl adipate 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 102472-53-7 (+/-)-cis-1-(toluene-4-sulfonyloxy)-2-[2-(toluene-4-sulfonyloxy)-ethyl]-cyclopentane 
• 109654-84-4 2-methyl-7,8,9,10-tetrahydro-5H-benzo[b]cyclopent[d]azepin-6-one 

Relevant academic research and scientific papers

Acyl acid derivative and preparation method and medical application thereof

The invention relates to an acyl acid derivative as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound represented by a general formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and the invention also relates to a use thereof as an active ingredient in the prevention and/or treatment of muscle atrophy-related diseases, including myogenic muscle atrophy, disuse muscle atrophy, senile muscle atrophy, neurogenic muscle atrophy, and a use in the prevention and/or treatment of obesity, fatty liver, cardiovascular and cerebrovascular diseases, metabolic diseases, and anti-aging, wherein the definition of each group in the general formula (I) is the same as the definition in the specification.

Rearrangements of α-Diazo-β-hydroxyketones for the Synthesis of Bicyclo[m.n.1]alkanones

Rhodium-catalyzed decomposition of fused bicyclic α-diazo-β-hydroxyketones results in good yields of bridged bicyclo[m.n.1]ketones via a rearrangement pathway.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF

The present invention relates to processes and intermediates useful in the preparation of of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

Direct enantioselective bronsted acid catalyzed N-acyliminium cyclization cascades of tryptamines and ketoacids

A direct enantio- and diastereoselective N-acyliminium cyclization cascade through chiral phosphoric acid catalyzed condensation of tryptamines with γ- and δ-ketoacid derivatives to provide architecturally complex heterocycles has been developed. The reac

SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

Facile synthesis of oxatricyclic systems with various ring sizes and substituents

A series of α-diazo carbonyl compounds having cyclopentanone, cyclohexanone and substituted cyclohexanone units with different tether lengths have been synthesized using diazomethane solution or methanesulphonyl azide. The above synthesized α-diazo carbon

RUTHENIUM-CATALYZED OXIDATION OF 2,3-EPOXYNORBORNANE. INFLUENCE OF THE NATURE OF THE REOXIDIZING REAGENT.

The nature of the reoxidizing reagent plays a decisive role in the outcome of the ruthenium-catalyzed oxidation of 2,3-epoxynorbornane.

Synthesis of Oxa- and Thia- analogs of Bicycloalkanes

A general and convenient synthetic approach of a variety of oxa- and thia- analogs of bicycloalkanes is described.This is illustrated by the synthesis of a series of 2-oxa(IIa-d)- and 2-thia(IIa-d)- analogs of bicyclooctane(I) on one hand and 4-oxa(Va-d)- and 4-thia(VIa-d)- analogs of bicyclodecane(IV) on the other.The analogs of I and IV are obtained by cyclohydration of the diols XIX and XXI respectively usung dil.H2SO4 or DMSO.The diols in turn are prepared starting from the keto acids VII.On the otherhand, treatment of di-tosylates XX and XXII of XIX and XXI with Na2S in refluxing ethanol affords the respective 2-thia(III)- and 4-thia(VI)- analogs of I and IV systems.The formation of oxolans(II) via oxidative cyclisation of the cycloalkaneethanols(XXIII) with lead tetraacetate is also described.